HRP20160859T1 - Modificirani proteini rsv f i postupci njihove upotrebe - Google Patents

Modificirani proteini rsv f i postupci njihove upotrebe

Info

Publication number
HRP20160859T1
HRP20160859T1 HRP20160859TT HRP20160859T HRP20160859T1 HR P20160859 T1 HRP20160859 T1 HR P20160859T1 HR P20160859T T HRP20160859T T HR P20160859TT HR P20160859 T HRP20160859 T HR P20160859T HR P20160859 T1 HRP20160859 T1 HR P20160859T1
Authority
HR
Croatia
Prior art keywords
rsv
procedures
modified proteins
proteins
modified
Prior art date
Application number
HRP20160859TT
Other languages
English (en)
Croatian (hr)
Inventor
Peter Pushko
Yingyun Wu
Michael Massare
Ye Liu
Gale Smith
Bin Zhou
Original Assignee
Novavax, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42310119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20160859(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novavax, Inc. filed Critical Novavax, Inc.
Publication of HRP20160859T1 publication Critical patent/HRP20160859T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20160859TT 2008-12-09 2009-12-09 Modificirani proteini rsv f i postupci njihove upotrebe HRP20160859T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12112608P 2008-12-09 2008-12-09
US16907709P 2009-04-14 2009-04-14
US22478709P 2009-07-10 2009-07-10
PCT/US2009/067269 WO2010077717A1 (en) 2008-12-09 2009-12-09 Modified rsv f proteins and methods of their use
EP09836751.9A EP2370099B1 (en) 2008-12-09 2009-12-09 Modified rsv f proteins and methods of their use

Publications (1)

Publication Number Publication Date
HRP20160859T1 true HRP20160859T1 (hr) 2016-09-23

Family

ID=42310119

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20160859TT HRP20160859T1 (hr) 2008-12-09 2009-12-09 Modificirani proteini rsv f i postupci njihove upotrebe
HRP20200871TT HRP20200871T1 (hr) 2008-12-09 2020-06-02 Izmjenjeni rsv f proteini i postupci njihove uporabe

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20200871TT HRP20200871T1 (hr) 2008-12-09 2020-06-02 Izmjenjeni rsv f proteini i postupci njihove uporabe

Country Status (23)

Country Link
US (7) US8715692B2 (enExample)
EP (3) EP3718566B1 (enExample)
JP (4) JP5813513B2 (enExample)
KR (2) KR101801213B1 (enExample)
CN (2) CN106146671B (enExample)
AU (1) AU2009333484B2 (enExample)
BR (1) BRPI0922867B8 (enExample)
CA (1) CA2746228C (enExample)
CY (2) CY1117757T1 (enExample)
DK (2) DK2370099T3 (enExample)
ES (3) ES2582005T3 (enExample)
HR (2) HRP20160859T1 (enExample)
HU (2) HUE051666T2 (enExample)
IL (2) IL213450B (enExample)
LT (1) LT3067064T (enExample)
MX (4) MX337932B (enExample)
PL (2) PL3067064T3 (enExample)
PT (2) PT2370099T (enExample)
RU (1) RU2531510C2 (enExample)
SG (2) SG10201500161XA (enExample)
SI (2) SI2370099T1 (enExample)
SM (1) SMT202000411T1 (enExample)
WO (1) WO2010077717A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160000902A1 (en) * 2003-07-11 2016-01-07 Novavax, Inc. Combination vaccine for respiratory syncytial virus and influenza
AU2009316680B2 (en) * 2008-11-18 2016-03-24 Takeda Vaccines, Inc. RSV F VLPs and methods of manufacture and use thereof
PL3067064T3 (pl) 2008-12-09 2020-11-02 Novavax, Inc. Zmodyfikowane białka f rsv i sposoby ich wykorzystania
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
SI3178490T1 (sl) * 2009-07-15 2022-08-31 Glaxosmithkline Biologicals S.A. Sestavki proteina F RSV-ja in postopki za pripravo le-teh
US20110097358A1 (en) * 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
PT2635257T (pt) 2010-11-05 2017-08-16 Novavax Inc Partículas semelhantes a vírus de glicoproteína de raiva (vlps)
WO2012089231A1 (en) * 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
HRP20190791T1 (hr) 2011-01-26 2019-06-28 Glaxosmithkline Biologicals Sa Režim imuniziranja protiv rsv
SI3275892T1 (sl) 2011-05-13 2020-06-30 Glaxosmithkline Biologicals S.A. Prefuzijski RSV F antigeni
EP2739307B1 (en) * 2011-08-01 2017-09-06 Emory University Vlps containing ligands and methods related thereto
EP2752199A4 (en) 2011-08-29 2015-04-29 Univ Tokushima RSV MUCOSA VACCINE
CA2849471A1 (en) * 2011-09-30 2013-04-04 Novavax, Inc. Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
CN103239734B (zh) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
WO2014019718A1 (en) 2012-08-01 2014-02-06 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
BR112015011389A2 (pt) 2012-11-20 2017-08-22 Glaxosmithkline Biologicals Sa Complexo f do vírus sincicial respiratório, métodos para produzir um complexo f do vírus sincicial respiratório e para indução de uma resposta imunológica a um f de rsv em um indivíduo, e, composição imunogênica
BR112015019126A2 (pt) * 2013-02-11 2017-08-22 Novavax Inc Vacina de combinação para vírus sincicial respiratório e influenza
AU2014239583B2 (en) * 2013-03-14 2020-07-02 Children's Healthcare Of Atlanta, Inc. Recombinant RSV with silent mutations, vaccines, and methods related thereto
DE102013004595A1 (de) * 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
EP3046579A1 (en) 2013-09-19 2016-07-27 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
WO2015195961A1 (en) * 2014-06-18 2015-12-23 Georgia State University And Research Foundation, Inc. Recombinant rsv reporter virus
JP6824154B2 (ja) * 2014-08-08 2021-02-03 ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
US10426829B2 (en) 2015-09-03 2019-10-01 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
WO2017075125A1 (en) 2015-10-29 2017-05-04 Emory University Chimeric RSV, Immunogenic Compositions, and Methods of Use
PE20181354A1 (es) 2015-12-23 2018-08-22 Pfizer Mutantes de proteina f de rsv
EP3808374A1 (en) 2016-04-05 2021-04-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f proteins for use in the prophylaxis of rsv infection
CN109069612A (zh) * 2016-04-05 2018-12-21 扬森疫苗与预防公司 针对rsv的疫苗
PE20190110A1 (es) 2016-05-30 2019-01-15 Janssen Vaccines And Prevention B V Proteinas f de prefusion del vrs estabilizadas
CN106011086A (zh) * 2016-06-15 2016-10-12 湖北省农业科学院畜牧兽医研究所 表达信号肽替换的呼吸道合胞病毒f蛋白的重组新城疫耐热疫苗株及制备方法
EP3595713A4 (en) 2017-03-15 2021-01-13 ModernaTX, Inc. Respiratory syncytial virus vaccine
BR112019019813A2 (pt) * 2017-03-30 2020-04-22 Univ Queensland moléculas quiméricas e usos das mesmas
LT3606942T (lt) 2017-04-04 2025-10-10 Savaiminės sąrankos baltymų nanostruktūros, eksponuojančios paramiksoviruso ir (arba) pneumoviruso f baltymus ir jų naudojimas
MX2019014719A (es) 2017-06-14 2020-08-03 Virometix Ag Peptidos ciclicos para proteccion contra el virus sincitial respiratorio.
ES3028362T3 (en) 2017-07-24 2025-06-19 Novavax Inc Methods and compositions for treating respiratory disease
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
AU2019228551B2 (en) 2018-02-28 2025-07-24 University Of Washington Self-assembling nanostructure vaccines
CA3092984A1 (en) 2018-03-19 2019-09-26 Novavax, Inc. Multivalent influenza nanoparticle vaccines
EP3775174A4 (en) * 2018-03-30 2022-07-06 Georgia State University Research Foundation, Inc. Respiratory syncytial virus (rsv) vaccines
CN112512567A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性呼吸道合胞病毒多肽
WO2020092365A1 (en) 2018-10-29 2020-05-07 Binh Ha Rsv virus-like particles and methods of use thereof
KR102725189B1 (ko) 2018-11-01 2024-10-31 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
PH12021550974A1 (en) 2018-11-13 2022-05-02 Janssen Vaccines & Prevention Bv Stablized pre-fusion rsv f proteins
CN113260377B (zh) 2018-12-20 2025-08-22 维罗米蒂克斯股份公司 脂肽构建块和合成病毒样颗粒
US20220125909A1 (en) * 2019-02-11 2022-04-28 Emory University Chimeric rsv and hmpv f proteins, immunogenic compositions, and methods of use
KR102679227B1 (ko) 2019-02-28 2024-06-28 케이엠 바이올로직스 가부시키가이샤 Rsv f/g 키메라 백신
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
IL295142A (en) * 2020-01-27 2022-09-01 Novavax Inc Coronavirus vaccine formulations
JP2023522249A (ja) 2020-04-22 2023-05-29 ビオンテック・ソシエタス・エウロパエア コロナウイルスワクチン
CN113855796B (zh) * 2021-07-30 2024-01-26 河北医科大学 卡介苗作为呼吸道合胞病毒灭活疫苗佐剂的应用
WO2023062651A1 (en) * 2021-10-13 2023-04-20 Padmanabh Patil Harshad Virus-like particles for respiratory syncytial virus and method of preparation thereof
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN115927751B (zh) * 2022-09-17 2024-12-20 宁夏大学 牛呼吸道合胞体病毒实时荧光定量pcr检测的引物探针组及检测方法
WO2024193380A1 (zh) * 2023-03-17 2024-09-26 成都威斯克生物医药有限公司 抗呼吸道合胞病毒感染的疫苗
WO2025026448A1 (zh) * 2023-08-03 2025-02-06 广州穗和生物技术有限公司 修饰的呼吸道合胞病毒f蛋白及其用途
CN119504955A (zh) * 2023-08-25 2025-02-25 深圳瑞吉生物科技有限公司 呼吸道合胞病毒抗原性多肽、核酸及疫苗
CN119569835A (zh) * 2023-09-07 2025-03-07 北京科兴中维生物技术有限公司 呼吸道合胞病毒f蛋白及其应用
WO2025101668A1 (en) 2023-11-06 2025-05-15 Novavax, Inc. Intranasal immunogenic compositions
CN117645655B (zh) * 2024-01-26 2024-05-24 普大生物科技(泰州)有限公司 一种肺炎球菌多糖-rsv重组蛋白结合疫苗及其制备方法
WO2025201243A1 (zh) * 2024-03-25 2025-10-02 中国医学科学院医学生物学研究所 重组呼吸道合胞病毒融合前f蛋白突变体和其用途
CN118146321B (zh) * 2024-03-27 2024-08-27 普大生物科技(泰州)有限公司 一种rsv重组蛋白疫苗及其制备方法
CN118480560B (zh) * 2024-07-09 2024-11-26 北京悦康科创医药科技股份有限公司 呼吸道合胞病毒mRNA疫苗及其制备方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
GB8914968D0 (en) * 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
ES2370937T3 (es) 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
NZ512980A (en) 1998-12-17 2003-07-25 Aventis Pasteur Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
JP5118798B2 (ja) 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
BR0114392A (pt) 2000-10-02 2003-09-02 Glaxosmithkline Biolog Sa Formulação de vacina, método para produzir uma formulação de vacina, uso de uma preparação de vacina contra rsv dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por rsv
WO2003068163A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
CA2523657A1 (en) 2003-04-25 2005-03-31 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
AU2004269320B2 (en) * 2003-06-20 2009-12-24 Protein Sciences Corporation Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
EP1713824A2 (en) 2003-12-10 2006-10-25 The Uab Research Foundation Recombinant viruses with heterologous envelope proteins
US8846607B2 (en) 2004-10-29 2014-09-30 President And Fellows Of Harvard College Particles for treatment of pulmonary infection
US20060216700A1 (en) 2005-03-10 2006-09-28 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
EP2040746A4 (en) 2006-06-19 2009-12-16 Progenics Pharm Inc METHODS OF RECOVERING STABILIZED FORMULATIONS OF RETROVIRAL ENVELOPE (ENV) PROTEIN TRIMERS
US20080233150A1 (en) * 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
WO2008133663A2 (en) * 2006-11-30 2008-11-06 Government Of The United States Of America, As Represented By The Secretary, Codon modified immunogenic compositions and methods of use
EP1972348A1 (en) * 2007-03-14 2008-09-24 Pierre Fabre Medicament Novel vaccine composition for the treatment of respiratory infectious diseases
US20100203071A1 (en) * 2007-03-21 2010-08-12 Norman Blais Chimeric antigens
WO2009012487A2 (en) 2007-07-19 2009-01-22 Novavax, Inc. Chimeric varicella zoster virus-virus like particles
US20100239671A1 (en) 2007-11-06 2010-09-23 Edelman Elazer R Tissue-Engineered Endothelial and Epithelial Implants Differentially and Synergistically Regulate Tissue Repair
WO2009079796A1 (en) 2007-12-24 2009-07-02 Id Biomedical Corporation Of Quebec Recombinant rsv antigens
CA2716546A1 (en) 2008-02-25 2009-09-03 Novavax, Inc. Sugar glassified virus like particles (vlps)
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
PL3067064T3 (pl) 2008-12-09 2020-11-02 Novavax, Inc. Zmodyfikowane białka f rsv i sposoby ich wykorzystania
WO2010138193A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
AU2010264688A1 (en) * 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Recombinant RSV antigens
SI3178490T1 (sl) 2009-07-15 2022-08-31 Glaxosmithkline Biologicals S.A. Sestavki proteina F RSV-ja in postopki za pripravo le-teh
PT2635257T (pt) 2010-11-05 2017-08-16 Novavax Inc Partículas semelhantes a vírus de glicoproteína de raiva (vlps)
CN102107003A (zh) 2011-01-05 2011-06-29 重庆大学 一种猪繁殖与呼吸综合症病毒体疫苗及其制备方法
EP2729168A2 (en) 2011-07-06 2014-05-14 Novartis AG Immunogenic compositions and uses thereof
CA2849471A1 (en) 2011-09-30 2013-04-04 Novavax, Inc. Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
BR112015019126A2 (pt) 2013-02-11 2017-08-22 Novavax Inc Vacina de combinação para vírus sincicial respiratório e influenza
RU2531235C2 (ru) 2013-02-15 2014-10-20 Общество с ограниченной ответственностью "Универсальные БиоСистемы" (ООО "УБС") Поливалентная вакцина против гриппа на основе гибридного белка
SG11201508567XA (en) 2013-04-25 2015-11-27 Crucell Holland Bv Stabilized soluble prefusion rsv f polypeptides
AU2014100888A4 (en) 2014-08-07 2014-09-11 Novartis Ag Virus clearance and protein purification methods
WO2017000105A1 (zh) * 2015-06-29 2017-01-05 尚平 便携式加湿器
US10426829B2 (en) 2015-09-03 2019-10-01 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity

Also Published As

Publication number Publication date
JP2012511579A (ja) 2012-05-24
EP2370099A1 (en) 2011-10-05
JP6782289B2 (ja) 2020-11-11
SI3067064T1 (sl) 2020-09-30
JP6462048B2 (ja) 2019-01-30
HUE029037T2 (en) 2017-01-30
CN106146671A (zh) 2016-11-23
ES2987238T3 (es) 2024-11-14
HK1161690A1 (zh) 2012-08-03
MX358836B (es) 2018-09-05
EP3067064B1 (en) 2020-05-13
US9731000B2 (en) 2017-08-15
SG172022A1 (en) 2011-07-28
CN102307591B (zh) 2016-08-03
JP2015171378A (ja) 2015-10-01
RU2011128371A (ru) 2013-01-20
DK2370099T3 (en) 2016-08-01
SG10201500161XA (en) 2015-03-30
PL2370099T3 (pl) 2016-10-31
US12357684B2 (en) 2025-07-15
PL3067064T3 (pl) 2020-11-02
US20190134187A1 (en) 2019-05-09
US11052146B2 (en) 2021-07-06
AU2009333484B2 (en) 2014-12-11
HUE051666T2 (hu) 2021-03-29
EP3718566A1 (en) 2020-10-07
ES2582005T3 (es) 2016-09-08
US20150265698A1 (en) 2015-09-24
ES2796725T3 (es) 2020-11-30
IL247341B (en) 2018-04-30
BRPI0922867B1 (pt) 2020-09-29
US20230293667A1 (en) 2023-09-21
PT2370099T (pt) 2016-07-14
EP3067064A1 (en) 2016-09-14
KR20160148720A (ko) 2016-12-26
US9675685B2 (en) 2017-06-13
IL213450A0 (en) 2011-07-31
JP5813513B2 (ja) 2015-11-17
EP3718566B1 (en) 2024-06-12
MX337932B (es) 2016-03-28
DK3067064T3 (da) 2020-06-08
US10022437B2 (en) 2018-07-17
WO2010077717A1 (en) 2010-07-08
RU2531510C2 (ru) 2014-10-20
CN102307591A (zh) 2012-01-04
US20150359872A1 (en) 2015-12-17
CA2746228A1 (en) 2010-07-08
US20100239617A1 (en) 2010-09-23
BRPI0922867A2 (pt) 2016-09-27
US9717786B2 (en) 2017-08-01
BRPI0922867B8 (pt) 2021-05-25
KR101801213B1 (ko) 2017-11-24
PT3067064T (pt) 2020-06-16
HRP20200871T1 (hr) 2020-10-30
IL213450B (en) 2018-02-28
EP2370099A4 (en) 2013-05-29
JP6162751B2 (ja) 2017-07-12
EP2370099B1 (en) 2016-04-20
US20140294879A1 (en) 2014-10-02
JP2019069982A (ja) 2019-05-09
MX345700B (es) 2017-02-10
SI2370099T1 (sl) 2016-08-31
LT3067064T (lt) 2020-09-10
SMT202000411T1 (it) 2020-09-10
MX2011006205A (es) 2011-09-01
JP2018007655A (ja) 2018-01-18
US8715692B2 (en) 2014-05-06
CA2746228C (en) 2021-05-18
AU2009333484A1 (en) 2011-07-21
KR101691574B1 (ko) 2017-01-02
CY1123152T1 (el) 2021-10-29
CN106146671B (zh) 2020-03-31
KR20110112328A (ko) 2011-10-12
CY1117757T1 (el) 2017-05-17
US20150266930A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
HRP20160859T1 (hr) Modificirani proteini rsv f i postupci njihove upotrebe
NL300891I2 (nl) Lotilaner en zouten daarvan
PL2942355T3 (pl) Nie-hemolityczne białka fuzyjne llo i ich zastosowanie
DK3118220T3 (da) Protein
DK2307543T3 (da) Forbedret proteinekspressionssystem
PL2358756T3 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
EP2215246A4 (en) PROTEIN SCAFFOLDS
DK2046826T3 (da) Exendin-fusionsproteiner
EP2207803A4 (en) Cd9-specific human antibodies
BRPI0910668A2 (pt) inibidores de proteína quinases
EP2131749A4 (en) Surgical stapling apparatus
DE602009000580D1 (de) Endoskopsystem
DK2361045T3 (da) Kirurgisk orienteringssystem
BRPI0907064A2 (pt) "métodos e sistemas"
PL2256672T3 (pl) Transponder i postać książki
BRPI0814971A2 (pt) Proteína
BRPI0806538A2 (pt) Derivados de glicinamida de espiropiperidina
BRPI0815203A2 (pt) gel contendo pirfenidona
EP2315771A4 (en) GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF
EP2388320A4 (en) Anti-hs6st2 antibodies and use thereof
BRPI0814800A2 (pt) Derivados de aminoácidos
HRP20160578T1 (hr) Supstituirani furankarboksamidi i njihova upotreba
DK2310037T3 (da) Conglutin-gamma as-medikament og -kosttilskudpatentkrav